Key takeaways
- ~14M US adults with a physician COPD diagnosis (~4-5% of adults), per CDC Behavioral Risk Factor Surveillance System national estimates
- 41.4% of adults at higher COPD risk who had actually received a breathing test — evidence of systematic underdiagnosis (Prev Chronic Dis 2024, PMID 38723273)
- 4th leading cause of death in the US in 2019; COPD drives the majority of chronic lower respiratory disease mortality (MMWR 2022, PMID 35511711)
~14 million US adults carry a COPD diagnosis, roughly one in seven at-risk adults is never tested, and the eosinophil count now splits the treated population into biologic-eligible and not
COPD remains one of the largest chronic-disease populations in the United States and a leading cause of death — it accounts for the majority of chronic lower respiratory disease deaths and was the fourth leading US cause of death in 2019 (CDC MMWR). Yet diagnosed prevalence understates the true burden: national survey data show a substantial fraction of at-risk adults have never received a breathing test, leaving a large undiagnosed pool that never enters the treatment pathway.
Diagnosis is spirometric: a post-bronchodilator FEV1/FVC below 0.70, and management is now staged by the GOLD A-E system, which in its 2023 revision replaced the old C/D groups with a single exacerbator group 'E'. The pivotal shift for commercial strategy is biological: the blood eosinophil count (>=300 cells/uL) is the gate that determines whether an exacerbating patient can reach the first COPD biologic, converting a symptom-and-history pathway into a biomarker-stratified one.
The US COPD pathway runs diagnosis to endotype: spirometry confirms it, GOLD A-E stages it, and the eosinophil count now decides who reaches a biologic
| Stage / measure | Definition / criterion | US figure or driver | Source |
|---|---|---|---|
| Diagnosed prevalence | Adults with self-reported physician-diagnosed COPD | ~14 million US adults (~4-5% of adults) | CDC BRFSS national estimates |
| Undiagnosed / at-risk | Symptomatic or at-risk adults without a COPD diagnosis | ~15% of screened adults at higher risk; only 41.4% had a breathing test | Prev Chronic Dis 2024, PMID 38723273 |
| Diagnostic criterion | Post-bronchodilator spirometry | FEV1/FVC < 0.70 confirms persistent airflow obstruction | GOLD 2024 report |
| Severity / risk class | GOLD A-E (2023 revision) by symptom burden + exacerbation history | Group E = >=2 moderate or >=1 hospitalized exacerbation per year | GOLD 2023 report |
| Type 2 / eosinophilic endotype | Blood eosinophil count threshold | >=300 cells/uL — biologic-eligibility gate (dupilumab trial entry) | BOREAS/NOTUS eligibility, PMIDs 37272521, 38767614 |
| Mortality burden | COPD-attributed deaths, adults >=25 | 4th leading US cause of death (2019); rates declining in men, flat/rising in women | MMWR 2022, PMID 35511711 |
Sources: Diagnosed prevalence: CDC Behavioral Risk Factor Surveillance System (BRFSS) national COPD estimates. Underdiagnosis and breathing-test receipt: Prev Chronic Dis 2024, PMID 38723273, doi:10.5888/pcd21.230399. Mortality burden and rank: MMWR Morb Mortal Wkly Rep 2022, PMID 35511711, doi:10.15585/mmwr.mm7118a1. Eosinophil >=300 endotype gate: BOREAS (NEJM 2023, PMID 37272521) and NOTUS (NEJM 2024, PMID 38767614) trial entry criteria. Diagnostic and staging criteria: GOLD 2023/2024 reports. All PMIDs verified live via PubMed.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- How big is the biologic-eligible slice once you layer eosinophil >=300 onto the triple-therapy-failure population? • A funnel from diagnosed prevalence to symptomatic-exacerbator to eosinophilic endotype, sizing the reachable add-on pool
- Where does the undiagnosed pool sit in the pathway, and what unlocks it? • A view of the missing spirometry step and the diagnostic gap that caps the entire market's ceiling
- How does the GOLD A-E reclassification change who gets escalated to ICS-containing and add-on therapy? • Mapping of the 2023 GOLD groups to treatment escalation triggers and eosinophil-guided ICS decisions
What's inside
-
1 · Disease Biology & the GOLD A-E Severity Framework 4 pp
- The 2023 GOLD revision replacing the old C/D groups with a single exacerbator group 'E'
- Why blood eosinophil count (>=300 cells/uL) is now the biomarker gate determining biologic eligibility within GOLD staging
-
2 · ~14 Million Diagnosed, Yet Only 4 in 10 At-Risk Adults Ever Tested 5 pp
- The ~14 million US adults (4-5% of adults) with a physician COPD diagnosis, per CDC BRFSS
- The 41.4% breathing-test receipt rate among at-risk adults, evidence of systematic underdiagnosis (PMID 38723273)
-
3 · A Mortality Burden Moving in Opposite Directions by Sex 4 pp
- COPD's status as the 4th leading US cause of death in 2019, driving the majority of chronic lower respiratory disease mortality (MMWR)
- The divergent mortality trend: rates declining in men, flat-to-rising in women
-
4 · Severity Segmentation: GOLD Group E and the Exacerbation-Frequency Gate 4 pp
- The Group E threshold of >=2 moderate or >=1 hospitalized exacerbation per year that defines the highest-severity segment
- How exacerbation-frequency staging, not symptom burden alone, now drives treatment escalation
-
5 · Diagnostic Pathway: Post-Bronchodilator Spirometry & the FEV1/FVC 0.70 Threshold 5 pp
- The post-bronchodilator FEV1/FVC <0.70 spirometric criterion that confirms persistent airflow obstruction
- Why the missing spirometry step caps the entire market's diagnostic ceiling
-
6 · The Eosinophil-Gated Biologic-Eligible Pool Inside the Undiagnosed Reservoir 3 pp
- The funnel from ~14 million diagnosed patients through symptomatic exacerbators to the eos >=300 biologic-eligible endotype
- How the undiagnosed reservoir, given the 41.4% testing rate, still bounds the addressable biologic pool
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx delivers US COPD disease landscape built for pharma and biotech commercial, access, and medical affairs teams. Custom assessment in 72 hours.
- 1. Submit your requestUse the intake form to specify your indication, geography, and commercial question.
- 2. Scoping callAXLRx analyst confirms scope, comparators, and delivery format.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
Every AXLRx assessment is built from primary regulatory sources (FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer policy documentation — not secondary summaries. No secondary summaries, market research reports, or unverified estimates are used. Findings are independently verified before inclusion.
US COPD Disease Landscape sources: FDA Drugs@FDA (approvals and labels), CDC surveillance (BRFSS, MMWR), primary literature, GOLD reports, and live policy documentation.
- Underdiagnosis figures (15% higher-risk; 41.4% breathing test) and mortality rank (4th, 2019) verified against the CDC papers via live PubMed lookup.
- Eosinophil >=300 cells/uL threshold taken directly from the verified BOREAS/NOTUS trial eligibility criteria.
- Diagnosed prevalence (~14M) attributed to the CDC Behavioral Risk Factor Surveillance System (BRFSS), the authoritative US national surveillance source for COPD.
Frequently asked questions
Deliverables What formats are included with every assessment?
Every commissioned assessment includes three deliverables: a 20–30 page PDF analyst assessment with verified sources and exhibit tables, an editable Excel model (drug comparison grid, payer formulary data, or patient flow model — depending on deliverable type), and a 10–15 slide PowerPoint readout deck formatted for commercial team presentations. An optional 60-minute analyst readout call is included with all deliveries.
Sources What sources does AXLRx use, and how are findings verified?
AXLRx builds from primary sources only: FDA Drugs@FDA approval records and labels, CDC surveillance data, the GOLD strategy reports, and peer-reviewed epidemiology. No secondary summaries or market research reports. Every factual claim is independently verified before inclusion. Source citations are provided for all key data points in the delivered assessment.
Customisation Can I tailor the assessment to my specific question, geography, or comparator set?
Yes. The intake form captures your indication, target geography, key comparator drugs, and the specific commercial question you need answered. A scoping call confirms scope before research starts. Custom extensions (additional payer markets, pipeline agent profiles, or country-specific deep-dives) can be added to any standard assessment. Commission via the intake form to start.